window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

IDEFIRIX

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hansa Biopharma treats first commercial kidney transplant patient with Idefirix in Australia

    Hansa Biopharma has treated the first commercial Australian living donor [...]

    August 19, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Hansa completes €115M Idefirix licensing deal with SERB

    SERB has completed its €115 million licensing agreement with Hansa [...]

    July 2, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hansa Biopharma reports 135% Q4 revenue growth and BLA submission for imlifidase

    Hansa Biopharma has reported a 135% increase in fourth-quarter revenue [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cyllene gene therapy for bladder disorder gains FDA RMAT designation
    Categories: Drug Discovery & Development
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • NIH funds expanded access programme for Neurizon’s ALS therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top